AVADEL PHARMACEUTICALS PLC Quarterly Income Tax Expense (Benefit) in USD from Q1 2011 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Avadel Pharmaceuticals Plc quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q1 2011 to Q2 2024.
  • Avadel Pharmaceuticals Plc Income Tax Expense (Benefit) for the quarter ending June 30, 2024 was -$509K, a 666% decline year-over-year.
  • Avadel Pharmaceuticals Plc Income Tax Expense (Benefit) for the twelve months ending June 30, 2024 was -$427K, a 27.5% decline year-over-year.
  • Avadel Pharmaceuticals Plc annual Income Tax Expense (Benefit) for 2023 was -$501K, a 102% decline from 2022.
  • Avadel Pharmaceuticals Plc annual Income Tax Expense (Benefit) for 2022 was $26M.
  • Avadel Pharmaceuticals Plc annual Income Tax Expense (Benefit) for 2021 was -$15.8M, a 30.6% decline from 2020.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$427K -$509K -$599K -666% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 $172K $93K +$673K Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q4 2023 -$501K -$100K -$185K -218% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-29
Q3 2023 -$316K $89K +$19K +27.1% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-08
Q2 2023 -$335K $90K -$30.1M -99.7% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 $29.8M -$580K +$3.74M +86.6% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 $26M $85K +$4.43M Oct 1, 2022 Dec 31, 2022 10-K 2024-02-29
Q3 2022 $21.6M $70K +$5.17M Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-08
Q2 2022 $16.4M $30.2M +$34M Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-09
Q1 2022 -$17.5M -$4.32M -$1.72M -65.8% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 -$15.8M -$4.34M -$1.49M -52.3% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-29
Q3 2021 -$14.3M -$5.1M -$61K -1.21% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 -$14.3M -$3.77M -$9.06M -171% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 -$5.21M -$2.61M +$6.9M +72.6% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q4 2020 -$12.1M -$2.85M +$6.15M +68.3% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-16
Q3 2020 -$18.3M -$5.04M -$7.27M -326% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-08
Q2 2020 -$11M $5.29M +$3.51M +197% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-09
Q1 2020 -$14.5M -$9.51M -$9.14M -2443% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-10
Q4 2019 -$5.36M -$9M +$5.54M +38.1% Oct 1, 2019 Dec 31, 2019 10-K 2022-03-16
Q3 2019 -$10.9M $2.23M +$2.93M Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-09
Q2 2019 -$13.8M $1.78M +$2.12M Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-10
Q1 2019 -$15.9M -$374K +$1.95M +83.9% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-11
Q4 2018 -$17.9M -$14.5M -$17.1M -668% Oct 1, 2018 Dec 31, 2018 10-K 2021-03-09
Q3 2018 -$801K -$691K -$6.61M -112% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q2 2018 $5.81M -$342K -$7.71M -105% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-09
Q1 2018 $13.5M -$2.33M -$10.9M -127% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-08
Q4 2017 $24.4M $2.56M -$10.8M -80.8% Oct 1, 2017 Dec 31, 2017 10-K 2020-03-16
Q3 2017 $35.2M $5.92M +$2.47M +71.6% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-05
Q2 2017 $32.7M $7.37M -$79K -1.06% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-07
Q1 2017 $32.8M $8.54M +$1.23M +16.8% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-04
Q4 2016 $31.6M $13.3M +$3.72M +38.7% Oct 1, 2016 Dec 31, 2016 10-K 2019-03-15
Q3 2016 $27.8M $3.45M -$3.85M -52.7% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-09
Q2 2016 $31.7M $7.45M -$1.06M -12.4% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-09
Q1 2016 $32.7M $7.31M -$3.16M -30.2% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-10
Q4 2015 $35.9M $9.63M +$7.58M +370% Oct 1, 2015 Dec 31, 2015 10-K 2018-03-16
Q3 2015 $28.3M $7.3M +$7.33M Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-14
Q2 2015 $21M $8.51M +$8.37M +6109% Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-15
Q1 2015 $12.6M $10.5M +$13.3M Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-10
Q4 2014 -$644K $2.05M +$6.9M Oct 1, 2014 Dec 31, 2014 10-K 2017-03-28
Q3 2014 -$7.54M -$29K +$1.2M +97.6% Jul 1, 2014 Sep 30, 2014 6-K 2014-11-17
Q2 2014 -$8.74M $137K +$3.85M Apr 1, 2014 Jun 30, 2014 6-K 2015-12-31
Q1 2014 -$12.6M -$2.8M -$1.34M -91.7% Jan 1, 2014 Mar 31, 2014 6-K 2015-07-10
Q4 2013 -$11.2M -$4.85M -$122K -2.58% Oct 1, 2013 Dec 31, 2013 10-K 2016-03-15
Q3 2013 -$11.1M -$1.23M -$1.18M -2458% Jul 1, 2013 Sep 30, 2013 6-K 2014-11-17
Q2 2013 -$9.94M -$3.71M -$3.71M Apr 1, 2013 Jun 30, 2013 6-K 2014-08-08
Q1 2013 -$6.23M -$1.46M -$1.5M -3581% Jan 1, 2013 Mar 31, 2013 6-K 2014-07-08
Q4 2012 -$4.73M -$4.72M Oct 1, 2012 Dec 31, 2012 20-F/A 2015-10-01
Q3 2012 -$48K Jul 1, 2012 Sep 30, 2012 6-K 2014-01-15
Q2 2012 $1K* -$62K Apr 1, 2012 Jun 30, 2012 6-K 2013-12-06
Q1 2012 $42K +$19K +82.6% Jan 1, 2012 Mar 31, 2012 6-K 2012-09-13
Q2 2011 $63K Apr 1, 2011 Jun 30, 2011 6-K 2012-12-14
Q1 2011 $23K Jan 1, 2011 Mar 31, 2011 6-K 2012-09-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.